医学临床研究
  2025年7月25日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (7): 1075-1078    DOI: 10.3969/j.issn.1671-7171.2022.07.032
  论著 本期目录 | 过刊浏览 | 高级检索 |
缬沙坦氨氯地平治疗终末期肾病患者的临床疗效及对血清ROCK1、ROCK2水平的影响
成伟平1, 裴媛媛2*
1.榆林市第二医院药剂科,陕西 榆林 719000;
2.榆林市中医医院药剂科,陕西 榆林 719000
Effect of Valsartan and Amlodipine on Serum ROCK1 and ROCK2 Levels in Patients with End-stage Renal Disease
CHENG Wei-ping, PEI Yuan-yuan
Department of Pharmacy,Yulin No.2 Hospital,Yulin Shaanxi 719000
全文: PDF (1154 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨缬沙坦氨氯地平治疗终末期肾病(ESRD)患者的临床疗效及对血清Rho关联含卷曲螺旋蛋白激酶1(ROCK1)和ROCK2水平的影响。【方法】榆林市第二医院收治的ESRD患者92例,随机分为对照组和观察组,每组46例。两组均给予血液透析治疗,对照组采用氨氯地平,观察组采用缬沙坦氨氯地平降压治疗。比较两组治疗3个月后的疗效,并比较治疗前、治疗3个月后患者血压[收缩压(SBP)、舒张压(DBP)]、肾功能[血清肌酐(SCr)、尿素氮(BUN)]、血清ROCK1、ROCK2水平、生存质量[肾脏病与透析相关生存质量(KDTA)],统计治疗期间不良反应。【结果】观察组总有效率为91.30%(42/46),高于对照组的76.09%(35/46)(P<0.05)。治疗3个月后,观察组DBP、SBP水平,SCr、BUN,血清ROCK1、ROCK2水平均低于对照组(P<0.05)。治疗3个月后,观察组KDTA评分高于对照组(P<0.05)。观察组不良反应总发生率为17.39%(8/46),与对照组的13.04%(6/46)比较,差异无统计学意义(P>0.05)。【结论】缬沙坦氨氯地平治疗ESRD疗效显著,能降低患者血压水平,改善肾功能,降低血清ROCK1、ROCK2水平,提高患者生活质量,且安全性高,临床可推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
成伟平
裴媛媛
关键词 氨氯地平, 缬沙坦复方合剂/药理学肾病/药物疗法rho相关激酶类/血液治疗结果    
Abstract:【Objective】 To study the clinical efficacy of valsartan and amlodipine in the treatment of end-stage renal disease (ESRD) and its effect on the level of serum Rho associated coiled coil protein kinase1 (ROCK1) and ROCK2. 【Methods】Ninety-two patients with ESRD in Yulin No.2 Hospital were randomly divided into the control group and the observation group,with forty-six cases in each group. Both groups were treated with hemodialysis,in which the control group was treated with amlodipine and the observation group was treated with valsartan and amlodipine. The curative effects of the two groups after 3 months of treatment were compared,and blood pressure level[systolic blood pressure (SBP),diastolic blood pressure (DBP)],the renal function[serum creatinine (SCR),urea nitrogen (BUN)],serum ROCK1 and ROCK2 levels,and quality of life[kidney disease and dialysis related quality of life (KDTA)] before and after 3 months of treatment were compared in both groups. The adverse reactions during treatment were counted as well. 【Results】The total effective rate in the observation group was 91.30%(42/46),which was higher than 76.09%(35/46) in the control group (P<0.05). After 3 months of treatment,DBP,SBP,SCr,BUN, and levels of serum ROCK1 and ROCK2 in the observation group were lower than those in the control group (P<0.05). The KDTA score in the observation group after 3 months of treatment was higher than that in the control group (P<0.05). The incidence of adverse reactions was 17.39%(8/46) in the observation group and 13.04%(6/46) in the control group. There was no significant difference between the groups (P>0.05). 【Conclusion】Valsartan and amlodipine are effective in the treatment of ESRD. They can lower blood pressure,improve renal function,reduce the levels of serum ROCK1 and ROCK2,improve the quality of life,have high safety,and can be popularized in clinic.
Key wordsAmlodipine, Valsartan Drug Combination/PD    Nephrosis/DT    rho-Associated Kinases/BL    Treatment Outcome
收稿日期: 2022-01-17     
中图分类号:  R692  
通讯作者: *E-mail:415288112@qq.com   
引用本文:   
成伟平, 裴媛媛. 缬沙坦氨氯地平治疗终末期肾病患者的临床疗效及对血清ROCK1、ROCK2水平的影响[J]. 医学临床研究, 2022, 39(7): 1075-1078.
CHENG Wei-ping, PEI Yuan-yuan. Effect of Valsartan and Amlodipine on Serum ROCK1 and ROCK2 Levels in Patients with End-stage Renal Disease. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 1075-1078.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.07.032     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I7/1075
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn